Multiple myeloma (MM) is a disease of the elderly, with two-thirds of the affected population aged over 65 years. The introduction of novel agents in front-line treatment has improved the outcome of young as well as elderly patients. It is also contributing to an ever-increasing utilization of autologous stem cell transplantation (ASCT), by making a greater number of patients ⩾ 65 years eligible for this procedure. [1] [2] [3] Recent reports have documented a better event-free survival with the use of maintenance therapy (with interferon-alfa, bortezomib and immunomodulatory drugs) after ASCT in elderly patients. 4 Data on the benefits of bortezomib and immunomodulatory drugs in the induction phase followed by ASCT in the elderly population are also emerging. ) and granulocyte-colony stimulating factor (G-CSF) or pegfilgrastim administration.
For the historical control group, the median overall survival (OS) since ASCT was 45.7 months; treatment-related mortality (o 100 days from ASCT) was 0%. For the 34 patients of the study group, PMN engraftment was reached at a median of 12.5 days (range 11-33); treatment-related mortality was 2.9% (n = 1, CMV reactivation while in progressive disease); PFS from ASCT was 18.2 months for patients aged 65-79 years (n = 27) and 12.6 for patients ⩾ 70 years (n = 7); for patients aged 65-70 years median OS since ASCT was 64 months and for patients ⩾ 70 years 36.5 months; for patients treated with bortezomib/thalidomide in the induction phase, median OS was 64 months while it was 36.5 months for patients who had not received novel agents.
Our data confirm that ASCT is a safe procedure in selected elderly patients with MM. The engraftment period is comparable with that in young patients. 4 Prolonged PFS and OS have been obtained, mainly in populations aged 65-70 years. The use of novel agents in the induction phase before ASCT led to a significant survival advantage in this elderly population, encouraging a global treatment strategy in this setting. To better evaluate the impact of these agents before ASCT, as well as in the maintenance phase in the elderly MM population, larger studies are desirable. Given the first data on the predictive value of geriatric assessment in MM patients, 7 these scales should be prospectively evaluated also in the setting of ASCT and could be of great help for the physician in daily clinical practice.
